{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:40:27Z","timestamp":1782139227330,"version":"3.54.5"},"reference-count":38,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2015]]},"DOI":"10.1248\/bpb.b15-00243","type":"journal-article","created":{"date-parts":[[2015,10,31]],"date-time":"2015-10-31T22:06:46Z","timestamp":1446329206000},"page":"1689-1699","source":"Crossref","is-referenced-by-count":34,"title":["Association between Selective Serotonin Reuptake Inhibitor Therapy and Suicidality: Analysis of U.S. Food and Drug Administration Adverse Event Reporting System Data"],"prefix":"10.1248","volume":"38","author":[{"given":"Ryogo","family":"Umetsu","sequence":"first","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Abe","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University"},{"name":"Medical Database Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Ueda","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamato","family":"Kato","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinobu","family":"Matsui","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutomi","family":"Kinosada","sequence":"additional","affiliation":[{"name":"United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Lockhart P, Guthrie B. Trends in primary care antidepressant prescribing 1995\u20132007: a longitudinal population database analysis. <i>Br. J. Gen. Pract.<\/i>, <b>61<\/b>, e565\u2013e572 (2011).","DOI":"10.3399\/bjgp11X593848"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. <i>BMJ<\/i>, <b>330<\/b>, 389 (2005).","DOI":"10.1136\/bmj.330.7488.389"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Olfson M, Marcus MC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: A case control study. <i>Arch. Gen. Psychiatry<\/i>, <b>63<\/b>, 865\u2013872 (2006).","DOI":"10.1001\/archpsyc.63.8.865"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J, Treatment for Adolescents with Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. <i>JAMA<\/i>, <b>292<\/b>, 807\u2013820 (2004).","DOI":"10.1001\/jama.292.7.807"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Wijlaars LPMM, Nazareth I, Whitaker HJ, Evans SJW, Petersen I. Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis. <i>BMJ Open<\/i>, <b>3<\/b>, e003247 (2013).","DOI":"10.1136\/bmjopen-2013-003247"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Didham RC, McConnell DW, Blair HJ, Reith DM. Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication. <i>Br. J. Clin. Pharmacol.<\/i>, <b>60<\/b>, 519\u2013525 (2005).","DOI":"10.1111\/j.1365-2125.2005.02480.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. <i>BMJ<\/i>, <b>330<\/b>, 396 (2005).","DOI":"10.1136\/bmj.330.7488.396"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. <i>Arch. Gen. Psychiatry<\/i>, <b>63<\/b>, 332\u2013339 (2006).","DOI":"10.1001\/archpsyc.63.3.332"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. <i>CMAJ<\/i>, <b>180<\/b>, 291\u2013297 (2009).","DOI":"10.1503\/cmaj.081514"},{"key":"10","unstructured":"10) FDA. \u201cQuestions and Answers on Antidepressant Use in Children, Adolescents, and Adults: May, 2007.\u201d: \u2039http:\/\/www.fda.gov\/drugs\/drugsafety\/informationbydrugclass\/ucm096321.htm\u203a, cited 17 March, 2015."},{"key":"11","unstructured":"11) FDA. \u201cRevisions to Product Labeling.\u201d: \u2039http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/InformationbyDrugClass\/UCM173233.pdf\u203a, cited 17 March 2015."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. <i>Am. J. Psychiatry<\/i>, <b>163<\/b>, 1898\u20131904 (2006).","DOI":"10.1176\/ajp.2006.163.11.1898"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. <i>Int. J. Med. Sci.<\/i>, <b>10<\/b>, 796\u2013803 (2013).","DOI":"10.7150\/ijms.6048"},{"key":"14","unstructured":"14) Egberts AC, Meyboom RH, van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. <i>Drug Saf.<\/i>, <b>25<\/b>, 453\u2013458 (2002)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. <i>Clin. Pharmacol. Ther.<\/i>, <b>91<\/b>, 1010\u20131021 (2012).","DOI":"10.1038\/clpt.2012.50"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Suzuki Y, Suzuki H, Umetsu R, Uranishi H, Abe J, Nishibata Y, Sekiya Y, Miyamura N, Hara H, Tsuchiya T, Kinosada Y, Nakamura M. The analysis of the interaction between clopidogrel, aspirin and proton pump inhibitors using the FDA Adverse Event Reporting System database. <i>Biol. Pharm. Bull.<\/i>, <b>38<\/b>, 680\u2013686 (2015).","DOI":"10.1248\/bpb.b14-00191"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Gr\u00e9goire F, Pariente A, Fourrier-Reglat A, Haramburu F, B\u00e9gaud B, Moore N. A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding. <i>Br. J. Clin. Pharmacol.<\/i>, <b>66<\/b>, 142\u2013145 (2008).","DOI":"10.1111\/j.1365-2125.2008.03176.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. <i>Clin. Pharmacol. Ther.<\/i>, <b>82<\/b>, 157\u2013166 (2007).","DOI":"10.1038\/sj.clpt.6100258"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. <i>Acta Diabetol.<\/i>, <b>50<\/b>, 569\u2013577 (2013).","DOI":"10.1007\/s00592-011-0340-7"},{"key":"20","unstructured":"20) Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, Tang A, Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y, Wishart DS. DrugBank 4.0: shedding new light on drug metabolism. <i>Nucleic Acids Res.<\/i>, <b>42<\/b> (D1), D1091\u2013D1097 (2014)."},{"key":"21","unstructured":"21) Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. DrugBank 3.0: a comprehensive resource for \u2018omics\u2019 research on drugs. <i>Nucleic Acids Res.<\/i>, <b>39<\/b> (Database), D1035\u2013D1041 (2011)."},{"key":"22","unstructured":"22) Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. <i>Nucleic Acids Res.<\/i>, <b>36<\/b> (Database), D901\u2013D906 (2008)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. DrugBank: a comprehensive resource for <i>in silico<\/i> drug discovery and exploration. <i>Nucleic Acids Res.<\/i>, <b>34<\/b>, D668\u2013D672 (2006).","DOI":"10.1093\/nar\/gkj067"},{"key":"24","unstructured":"24) Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, Hegerl U, Lonnqvist J, Malone K, Marusic A, Mehlum L, Patton G, Phillips M, Rutz W, Rihmer Z, Schmidtke A, Shaffer D, Silverman M, Takahashi Y, Varnik A, Wasserman D, Yip P, Hendin H. Suicide prevention strategies: a systematic review. <i>JAMA<\/i>, <b>294<\/b>, 2064\u20132074 (2005)."},{"key":"25","unstructured":"25) Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Signalling possible drug\u2013drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. <i>Br. J. Clin. Pharmacol.<\/i>, <b>47<\/b>, 689\u2013693 (1999)."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) van Puijenbroek EP, Egberts AC, Heerdink ER, Leufkens HG. Detecting drug\u2013drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>56<\/b>, 733\u2013738 (2000).","DOI":"10.1007\/s002280000215"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Qian Y, Ye X, Du W, Ren J, Sun Y, Wang H, Luo B, Gao Q, Wu M, He J. A computerized system for detecting signals due to drug\u2013drug interactions in spontaneous reporting systems. <i>Br. J. Clin. Pharmacol.<\/i>, <b>69<\/b>, 67\u201373 (2010).","DOI":"10.1111\/j.1365-2125.2009.03557.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. <i>Pharmacoepidemiol. Drug Saf.<\/i>, <b>11<\/b>, 3\u201310 (2002).","DOI":"10.1002\/pds.668"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Toprak S, Cetin I, Guven T, Can G, Demircan C. Self-harm, suicidal ideation and suicide attempts among college students. <i>Psychiatry Res.<\/i>, <b>187<\/b>, 140\u2013144 (2011).","DOI":"10.1016\/j.psychres.2010.09.009"},{"key":"30","unstructured":"30) Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. <i>BMJ<\/i>, <b>350<\/b> (feb18 32), h517 (2015)."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Baldessarini RJ, Pompili M, Tondo L. Suicidal risk in antidepressant drug trials. <i>Arch. Gen. Psychiatry<\/i>, <b>63<\/b>, 246\u2013248 (2006).","DOI":"10.1001\/archpsyc.63.3.246"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data Mining Techniques in Pharmacovigilance. <i>Analysis of the Publicly Accesssible FDA Adverse Event Reporting System<\/i> (<i>AERS<\/i>). (Karahoca A ed.) Data Mining Applications in Engineering and Medicine. Intech, pp. 255\u2013302 (2012).","DOI":"10.5772\/50095"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, Kerse N, Macgillivray S. Antidepressants <i>versus<\/i> placebo for depression in primary care. <i>Cochrane Database Syst. Rev.<\/i>, <b>3<\/b>, CD007954 (2009).","DOI":"10.1002\/14651858.CD007954"},{"key":"34","unstructured":"34) Gibbons RD, Hur K, Brown C, Davis JM, Mann J. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. <i>Arch. Gen. Psychiatry<\/i>, <b>69<\/b>, 572\u2013579 (2012)."},{"key":"35","unstructured":"35) Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. <i>J. Psychiatry Neurosci.<\/i>, <b>28<\/b>, 331\u2013337 (2003)."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? <i>Curr. Med. Chem.<\/i>, <b>6<\/b>, 469\u2013480 (1999).","DOI":"10.2174\/0929867306666220330184544"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. <i>Drug Saf.<\/i>, <b>29<\/b>, 385\u2013396 (2006).","DOI":"10.2165\/00002018-200629050-00003"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. <i>Br. J. Clin. Pharmacol.<\/i>, <b>72<\/b>, 905\u2013908 (2011).","DOI":"10.1111\/j.1365-2125.2011.04037.x"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/38\/11\/38_b15-00243\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T23:17:25Z","timestamp":1653434245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/38\/11\/38_b15-00243\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b15-00243","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}